Capitol Health (ASX:CAJ) secured shareholder approval on Monday relating to the company's proposed merger with Integral Diagnostics (ASX:IDX) through a scheme of arrangement, according to a same-day filing with the Australian bourse.
About 95% of the shareholders were present and voting during the meeting with 99.9% of all votes in favor of the resolution, the filing said.
Integral Diagnostics has been engaged with the Australian Competition and Consumer Commission regarding the potential divestment and is awaiting informal merger clearance from the regulator.
Once Integral Diagnostics receives merger clearance from the Australian Competition and Consumer Commission, the company will apply to the Court for approval of the scheme.
Earlier, Capitol Health said the Federal Court of Australia will hear on Dec. 4 its application seeking the approval of the scheme.
Shares of Capitol Health and Internal Diagnostics each fell 3% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.